Overview

• The phase 2 clinical trial involved 28 cancer patients with major depression who each received a single 25mg dose of psilocybin during a supervised therapy session.
• Half of participants achieved significant and sustained depression relief for up to two years, while 43% also saw enduring reductions in anxiety.
• About a quarter of patients maintained improved mood without need for additional psychedelic or antidepressant treatment.
• Investigators stress that therapist guidance was crucial, citing evidence that benefits are not observed when psilocybin is administered without professional support.
• Researchers recommend larger randomized controlled trials and studies on repeat dosing to validate these findings and explore broader clinical applications.